Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on oncology sales, which generate more than 28% of total revenues. Key cancer ...

Pharmaceutical companies hiked prices on hundreds of drugs so far in January, ushering in 2026 with steeper costs for everything from the COVID-19 vaccine to Ozempic despite the Trump administration's ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma’s strategy at J.P.